Ocular Therapeutix™ to Present at the 17th Annual BIO CEO & Investor Conference

BEDFORD, Mass.--()--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Brad Smith, Chief Financial Officer, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 4:30 p.m. Eastern Time at the Waldorf Astoria in New York City.

A live webcast will be accessible through Ocular’s website at www.ocutx.com in the Investors section under Calendar of Events. A replay of the presentation will also be available.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma, allergic conjunctivitis, and dry eye disease. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Contacts

Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
bsmith@ocutx.com
or
Burns McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich, 212-213-0006
kminarovich@burnsmc.com
or
Media:
Ocular Therapeutix, Inc.
Scott Corning
Vice President of Sales and Marketing
scorning@ocutx.com

Recent Stories

RSS feed for Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.